UAB will take part in global clinical trial for COVID-19 treatment

UAB will take part in a National Institutes of Health (NIH)-sponsored global clinical trial to evaluate the safety and efficacy of therapeutic agents in hospitalized adult patients who have been diagnosed with COVID-19 (coronavirus).  The drug remdesivir – which was developed based on research conducted at UAB in partnership with Gilead Sciences Inc. (NYSE: GILD) – will be first to be evaluated in a phase three clinical trial. The UAB site was activated on March 25 by the National Institute…